奥田 佑道 (オクダ ユウジ)

OKUDA Yuji

写真a

所属

大学院医学系研究科(医学専攻等)  医学専攻  機能展開医学系  呼吸器内科学講座

研究キーワード 【 表示 / 非表示

  • 呼吸器内科学

出身大学 【 表示 / 非表示

  •  
    -
    2008年03月

    秋田大学   医学部   卒業

取得学位 【 表示 / 非表示

  • 秋田大学 -  学士(医学)

職務経歴(学内) 【 表示 / 非表示

  • 2025年04月
    -
    継続中

    秋田大学   大学院医学系研究科(医学専攻等)   医学専攻   機能展開医学系   呼吸器内科学講座   特任助教  

  • 2018年02月
    -
    2025年03月

    秋田大学   高齢者医療先端研究センター   特任助教  

 

学位論文 【 表示 / 非表示

  • Low Plasma Concentration of Gefitinib in Patients with EGFR Exon 21 L858R Point Mutations Shortens Progression-Free Survival

    Yuji Okuda, Kazuhiro Sato, Kazuhisa Sudo, Yukiyasu Hasegawa, Mariko Asano, Hajime Miura, Masahide Takeda, Masaaki Sano, Hiroyuki Watanabe, Hiroyuki Kobayashi, Takenori Niioka, Masatomo Miura, Hiroshi Ito

    Cancer Chemotherapy and Pharmacology.    2018年03月

    国内共著

研究等業績 【 表示 / 非表示

    ◆原著論文【 表示 / 非表示

  • Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer

    Yokota H.

    Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  95 ( 1 ) 49 - 49   2025年12月

    研究論文(学術雑誌)  

    PURPOSE: The inflammatory cytokine interleukin (IL)-6 reduces the activity of drug metabolic enzymes and promotes tumor progression. We investigated the effect of IL-6 on the pharmacokinetics of osimertinib and the association between an IL-6 polymorphism and clinical outcomes in 30 patients with non-small cell lung cancer (NSCLC). METHODS: Osimertinib and IL-6 plasma concentrations were measured on day 15 after therapy initiation. The genotype of IL-6 1800796G > C was identified using polymerase chain reaction-restriction fragment length polymorphism. Risk factors affecting overall survival (OS) were assessed by Cox proportional hazard regression analysis. RESULTS: The IL-6 concentration was significantly correlated with the osimertinib trough plasma concentration (r = 0.423, P = 0.020) and area under the plasma concentration-time curve (r = 0.420, P = 0.021). The IL-6 concentration was significantly higher in patients with the IL-6 rs1800796G allele versus C/C genotype (P = 0.024). OS was significantly shorter in patients with the IL-6 rs1800796G allele versus C/C genotype (median: 15.1 vs. 48.9 months, P = 0.005). Univariate and multivariate analyses indicated that the IL-6 rs1800796G allele is an independent risk factor for OS (crude hazard ratio = 7.07; P = 0.014; adjusted hazard ratio = 6.38; P = 0.021). CONCLUSION: A higher IL-6 concentration was associated with reduced metabolic activity of osimertinib, leading to increased osimertinib exposure. As the IL-6 concentration was higher in NSCLC patients with the IL-6 rs1800796G allele, it might be an independent prognostic factor for patients treated with osimertinib.

    DOI PubMed

  • Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer

    Hayato Yokota, Ruriko Asahi, Yumiko Akamine, Mizuki Kobayashi, Hiyu Wakabayashi, Sho Sakamoto, Yuji Okuda, Kazuhiro Sato, Katsutoshi Nakayama, Masafumi Kikuchi

    Journal of Pharmaceutical Health Care and Sciences   10 ( 1 )   2024年12月

    研究論文(学術雑誌)  

    Background: Anamorelin, a drug to treat cancer cachexia, binds to ghrelin receptors and improves body weight and appetite. In clinical trials in Japan, patients experienced a 10.7% frequency of stimulant conduction system depression as a severe side effect. Although rare, anamorelin sometimes causes fatal arrhythmias. Because patients with cancer cachexia are often underweight, data on the safety of anamorelin in obese patients are lacking. We report a case of QT interval prolongation after anamorelin administration to an obese patient with non-small cell lung cancer. Case presentation: A female patient with a body mass index of 30 kg/m2 underwent immunotherapy for lung adenocarcinoma. She presented with severe weight loss, anorexia, and fatigue. She had no history of heart disease. On day 12, after administration of anamorelin 100 mg once daily, the patient developed nausea, diarrhea, and anorexia, which were considered cancer immunotherapy-induced immune-related adverse events, and she was admitted to the hospital. An electrocardiogram (ECG) on admission showed a QTc interval of 502 ms. On admission, her hepatic function was Child–Pugh class B, and anamorelin was discontinued the next day. On day 3 after anamorelin discontinuation, the QTc interval was prolonged by up to 557 ms, then decreased to 490 ms on day 6, and improved to 450 ms on day 16. Re-administration of anamorelin was avoided. Conclusions: When administering anamorelin to obese patients, we should be aware of the potential for stimulatory conduction system depression, as in underweight patients. Therefore, we should monitor patients by ECG from the early stages of anamorelin administration. Anamorelin is lipophilic, and its volume of distribution is increased in obese patients. Consequently, obese patients may continue to have QT interval prolongation after discontinuation of anamorelin, requiring long-term side-effect monitoring.

    DOI

  • Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer.

    Hayato Yokota, Ruriko Asahi, Yumiko Akamine, Mizuki Kobayashi, Hiyu Wakabayashi, Sho Sakamoto, Yuji Okuda, Kazuhiro Sato, Katsutoshi Nakayama, Masafumi Kikuchi

    Journal of pharmaceutical health care and sciences   10 ( 1 ) 33 - 33   2024年06月

    研究論文(学術雑誌)  

    BACKGROUND: Anamorelin, a drug to treat cancer cachexia, binds to ghrelin receptors and improves body weight and appetite. In clinical trials in Japan, patients experienced a 10.7% frequency of stimulant conduction system depression as a severe side effect. Although rare, anamorelin sometimes causes fatal arrhythmias. Because patients with cancer cachexia are often underweight, data on the safety of anamorelin in obese patients are lacking. We report a case of QT interval prolongation after anamorelin administration to an obese patient with non-small cell lung cancer. CASE PRESENTATION: A female patient with a body mass index of 30 kg/m2 underwent immunotherapy for lung adenocarcinoma. She presented with severe weight loss, anorexia, and fatigue. She had no history of heart disease. On day 12, after administration of anamorelin 100 mg once daily, the patient developed nausea, diarrhea, and anorexia, which were considered cancer immunotherapy-induced immune-related adverse events, and she was admitted to the hospital. An electrocardiogram (ECG) on admission showed a QTc interval of 502 ms. On admission, her hepatic function was Child-Pugh class B, and anamorelin was discontinued the next day. On day 3 after anamorelin discontinuation, the QTc interval was prolonged by up to 557 ms, then decreased to 490 ms on day 6, and improved to 450 ms on day 16. Re-administration of anamorelin was avoided. CONCLUSIONS: When administering anamorelin to obese patients, we should be aware of the potential for stimulatory conduction system depression, as in underweight patients. Therefore, we should monitor patients by ECG from the early stages of anamorelin administration. Anamorelin is lipophilic, and its volume of distribution is increased in obese patients. Consequently, obese patients may continue to have QT interval prolongation after discontinuation of anamorelin, requiring long-term side-effect monitoring.

    DOI PubMed

  • Impact of the COVID-19 pandemic on the primary lung cancer screening program in Akita Prefecture, a region with the fastest aging population in Japan.

    Yuji Okuda, Kazuhiro Sato, Mariko Asano, Kentaroh Kudoh, Eiki Omoto, Yuka Izumiya, Sho Sakamoto, Masahide Takeda, Tatsunori Shimizu, Hidetaka Ota, Hirokazu Kurokawa, Yoshihiro Minamiya, Katsutoshi Nakayama

    Geriatrics & gerontology international ( Geriatrics and Gerontology International )  23 ( 8 ) 622 - 627   2023年07月

    研究論文(学術雑誌)  

    AIM: Akita Prefecture has the largest proportion of older inhabitants and the highest cancer mortality rate in Japan. Lung cancer is one of the biggest killers, and early detection is critical. Chest X-ray examinations are the main screening method for lung cancer; however, the COVID-19 pandemic has affected the screening system. Here, we evaluate how COVID-19 has affected lung cancer screening in Akita Prefecture. METHODS: Using the Akita General Health Corporation database, the average annual number of chest X-ray screening tests, close examinations and lung cancer diagnoses (stratified by sex and age) was evaluated during 2016-2019, and compared with the 2020 values. Furthermore, data on lung cancer registrations from 2018 to 2020 were obtained from the Collaborative Akita Prefecture Hospital-Based Cancer Registration System and analyzed. RESULTS: The average annual number of screening tests, close examinations and lung cancer diagnoses declined (by >50%) between 2016 to 2019 and 2020, especially among older people (aged ≥65 years). Furthermore, by stage, the number of patients with early-stage lung cancer (stage 0-I) decreased, and the number with advanced-stage cancer (stage IV) increased. CONCLUSIONS: The COVID-19 pandemic reduced lung cancer screening participation, especially among the older adult population in Akita Prefecture, resulting in a decrease in lung cancer diagnoses through screening. This might have reduced the number of early-stage cancer registrations. It is necessary to improve health education among the public regarding the importance of chest X-ray screening. Geriatr Gerontol Int 2023; ••: ••-••.

    DOI PubMed

  • Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.

    Kazuhisa Sudo, Kazuhiro Sato, Sho Sakamoto, Yukiyasu Hasegawa, Mariko Asano, Yuji Okuda, Masahide Takeda, Masaaki Sano, Hiroyuki Watanabe, Takanobu Shioya, Hiroshi Ito

    Anticancer research   37 ( 10 ) 5565 - 5571   2017年10月

    研究論文(学術雑誌)  

    BACKGROUND/AIM: To investigate the association between the number of circulating endothelial progenitor cells (EPCs) in non-squamous non-small cell lung cancer (NSCLC) and disease outcome, in combination chemotherapy with and without bevacizumab. MATERIALS AND METHODS: We retrospectively identified 25 non-squamous NSCLC cases, and divided them into high-EPC and low-EPC groups. Within each group, we compared disease outcomes, with or without the administration of bevacizumab. RESULTS: In the high-EPC group, chemotherapy with bevacizumab produced a significantly higher tumor reduction rate and objective response rate, with significantly longer progression-free survival, compared to chemotherapy without bevacizumab (p<0.001, p=0.010, and p<0.001, respectively). However, in the low-EPC group, there were no significant differences in disease outcomes in groups with versus those without bevacizumab. CONCLUSION: The number of EPCs may be a useful biomarker to guide decision-making in the use of bevacizumab in non-squamous NSCLC.

    PubMed

  • ◆⼤学,研究機関紀要【 表示 / 非表示

  • びまん性の肺動静脈奇形に対し、経カテーテルコイル塞栓 術を施行した4症例

    奥田 佑道、佐藤 一洋、坂本 祥、須藤 和久、長谷川 幸保、浅野 真理子、竹田 正秀、飯野 健二、佐野 正明、塩谷 隆信、橋本 学、渡邊 博之

    学内誌「秋田医学」     2018年03月  [査読有り]

    研究論文(大学,研究機関紀要)   国内共著

  • ◆その他【 表示 / 非表示

  • Treatment of Desquamative interstitial Pneumonia and Systemic Sclerosis with Corticosteroids and Immunosuppressants: A Case Report

    Omoto Eiki, Sato Kazuhiro, Takahashi Daichi, Kudoh Kentaroh, Shimada Kengo, Goshima Satoshi, Asahi Ruriko, Takita Yuri, Izumiya Yuka, Sakamoto Sho, Asano Mariko, Okuda Yuji, Takeda Masahide, Nakayama Katsutoshi

    Internal Medicine ( 一般社団法人 日本内科学会 )  advpub ( 0 )   2025年

    <p>A 66-year-old male ex-smoker presented with fatigue and non-productive cough, as well as a 2-year history of ground-glass opacities. Deterioration on chest radiography and increased KL-6 levels coincided with the progression of diffuse ground-glass opacities on high-resolution CT. Surgical lung biopsy revealed features consistent with desquamative interstitial pneumonia. Concurrent skin hardening and presence of anti-Scl-70 antibodies supported the diagnosis of systemic sclerosis. Treatment with oral corticosteroids proved to be effective, leading to radiographic improvement. The subsequent administration of cyclophosphamide and mycophenolate mofetil stabilized disease progression. </p>

    DOI PubMed CiNii Research

  • Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer

    Yokota H.

    Journal of Pharmaceutical Health Care and Sciences ( Journal of Pharmaceutical Health Care and Sciences )  10 ( 1 )   2024年12月

    DOI

  • Tracheal small cell carcinoma with RB1 Splice site mutation treated by chemoradiotherapy: A case report

    Sakamoto S.

    Current Problems in Cancer: Case Reports ( Current Problems in Cancer: Case Reports )  10   2023年06月

    DOI

  • 秋田県における新型コロナウイルス感染症の流行が高齢者の肺がん検診に与えた影響について

    奥田 佑道, 浅野 真理子, 佐藤 一洋, 大本 瑛己, 坂本 祥, 竹田 正秀, 清水 辰徳, 大田 秀隆, 中山 勝敏

    日本老年医学会雑誌 ( (一社)日本老年医学会 )  60 ( Suppl. ) 182 - 182   2023年05月

  • Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic–pharmacokinetic and exposure–response analysis

    Yokota H.

    Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  92 ( 4 ) 315 - 324   2023年

    PURPOSE: Because of the large interindividual variability of afatinib pharmacokinetics and adverse events, we evaluated the effects of polymorphisms in pregnane X receptor (NR1I2) and ABC transporters (ABCB1, ABCG2, and ABCC2) on the pharmacokinetics of afatinib. METHODS: The steady-state area under the concentration-time curve (AUC)0-24 of afatinib was analyzed using blood sampling just prior to and at 1, 2, 4, 6, 8, 12, and 24 h on day 15 after administration. RESULTS: The median oral clearance (CL/F) of afatinib in patients with the NR1I2 7635A allele was significantly lower than those in patients with the 7635G/G genotype (42.0 and 60.0 L/h, respectively, P = 0.025). There were no significant differences in afatinib CL/F between genotypes for NR1I2 8055C > T, -25385C > T, ABCB1, ABCG2, and ABCC2 polymorphisms. Based on the area under the receiver-operating characteristic curve, the threshold afatinib AUC0-24 value for prediction of dose reduction or withdrawal was 689 ng·h/mL at the best sensitivity (81.0%) and specificity (72.7%). In multivariate logistic regression analysis, an afatinib AUC0-24 above 689 ng·h/mL was independently associated with increased risk of dose reduction or withdrawal (OR: 11.66, P = 0.012). CONCLUSIONS: The NR1I2 7635A allele was related to a lower afatinib CL/F. Based on the AUC of 689 ng h/mL and CL/F, the optimal doses for patients with the NR1I2 7635G/G genotype and 7635A allele were recommended to be set at 40 and 30 mg/day, respectively, and subsequent adjustment of the maintenance dose based on the plasma concentrations of afatinib may be necessary to avoid afatinib-related adverse events.

    DOI PubMed

  • 全件表示 >>